According to GlobalData’s company profile on Ascendis Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Ascendis Pharma‘s grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Combination of cnp agonist and biologically active moiety for growth stimulation
A recently filed patent (Publication Number: US20230302091A1) describes a method for treating disorders that benefit from stimulating growth in patients. The method involves administering a CNP agonist, which is a compound that activates the CNP receptor, to the patient. The patient is also administered at least one other biologically active moiety or drug. The combination of the CNP agonist and the additional biologically active moiety or drug is effective in treating the disorder.
The CNP agonist used in the method can be a small molecule, natural product, oligonucleotide, polypeptide, or protein. It can also be a controlled-release CNP agonist, which allows for sustained release of the compound in the patient’s body.
The additional biologically active moiety or drug can be selected from a variety of options, including antihistamines, human anti-FGFR3 antibodies, soluble forms of human fibroblast growth factor receptor 3, tyrosine kinase inhibitors, statins, CNP agonists, growth hormone, IGF-1, ANP, BNP, inhibitors of peptidases and proteases, and inhibitors of NPR-C. Human growth hormone is specifically mentioned as one of the options.
The CNP agonist and the additional biologically active moiety or drug can be administered separately or formulated together in a single pharmaceutical composition for simultaneous administration.
The method is applicable to a range of disorders that benefit from stimulating growth, including achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, and many others.
The controlled-release CNP agonist used in the method can be water-soluble and can have specific chemical structures described by formulas (Ia) or (Ib) in the patent.
Overall, this patent describes a method for treating growth-related disorders by administering a CNP agonist in combination with other biologically active moieties or drugs. The method offers potential benefits for patients with various disorders and provides options for controlled-release formulations.
To know more about GlobalData’s detailed insights on Ascendis Pharma, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
Source link
#Patent #CNP #Agonist #Growth #Stimulation
